drugset / Trial / NCT05591079
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
Phase 2
Completed
99 enrolled
Cascade Pharmaceuticals, Inc
Laboratory Corporation of America · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)
Timeline
- Start
- 2023-02-10
- Primary completion
- 2023-11-09
- Completion
- 2023-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS0159 | Unknown | 1.4 mg | Oral |
| Subject | CS0159 | Unknown | 2 mg | Oral |